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 1
 Summary 
Cells of the innate immune system can recognize pathogens via a number of 
extracellular and intracellular receptors, such as Fc, mannose or Toll-like 
receptors. Recognition of these pathogens leads to the synthesis of 
inflammatory lipid mediators, the eicosanoids. The eicosanoids derive from 
arachidonic acid (AA), an ω-6 polyunsaturated fatty acid that mammals can 
incorporate directly through dietary sources or synthesize from linoleic acid. In 
cells, AA seldom occurs in free fatty acid form, and is almost always found 
esterified at the sn-2 position of glycerophospholipids. Thus, it has to be 
removed from there before any eicosanoid synthesis can occur. The enzymes 
involved in such a removal are the phospholipase A2s (PLA2s). The signaling 
pathways that mediate the production of eicosanoids by cells involved in innate 
immunity are not completely understood, but it is now clear that the calcium-
dependent cytosolic group IVA PLA2 (cPLA2α) is a critical enzyme in this 
process, and that, depending on cell type and stimulation conditions, regulatory 
cross-talk mechanisms exist between cPLA2α and other PLA2 enzymes present 
in the cells. 
 
Keywords: Arachidonic acid, innate immune response receptors, Ca2+-
dependent cytosolic phospholipase A2, secreted phospholipase A2 
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 Movilización de ácido araquidónico por estímulos de la respuesta inmune 
innata 
 
Resumen 
Las células del sistema inmune innato pueden reconocer patógenos mediante 
una serie de receptores extracelulares e intracelulares, tales como los 
receptores para Fc, receptores de manosa y receptores tipo Toll. El 
reconocimiento de estos patógenos conduce a la síntesis de mediadores 
lipídicos de la inflamación conocidos bajo el nombre colectivo de eicosanoides. 
Los eicosanoides derivan del ácido araquidónico (AA), un ácido graso ω-6 
poliinsaturado que los mamíferos pueden incorporar directamente a través la 
dieta o sintetizar a partir de ácido linoleico. El AA no se halla nunca en forma 
libre, sino esterificando la posición sn-2 de los glicerofosfolípidos de membrana. 
Por ello, antes de que se produzca la síntesis de eicosanoides, el AA tiene que 
ser liberado de los fosfolípidos. Las enzimas involucradas en tal liberación son 
las fosfolipasas A2 (PLA2). Aunque las rutas de señalización que median la 
producción de eicosanoides por células involucradas en inmunidad innata no 
están bien caracterizadas, se ha demostrado de modo concluyente que la 
fosfolipasa A2 citosólica de grupo IVA (cPLA2α) es una enzima fundamental en 
este proceso y que, dependiendo del tipo celular y de las condiciones de 
estimulación, existen mecanismos reguladores de cross-talk entre la cPLA2α y 
otras enzimas con actividad PLA2 presentes en las células. 
 
Palabras clave: Ácido araquidónico, receptores de la respuesta inmune innata, 
fosfolipasa A2 citosólica dependiente de Ca2+, fosfolipasa A2 secretada 
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 Abbreviations 
AA, arachidonic acid; COX-2, cyclooxygenase-2; cPLA2, Ca2+-dependent 
cytosolic phospholipase A2; CR3, complement receptor 3; CLR, C-type lectin 
receptor; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3-
grabbing non-integrin; FcR, fragment c receptor; fMLP: formyl-methionyl-leucyl-
phenylalanine; iNOS: nitric oxide synthase; iPLA2, Ca2+-independent cytosolic 
PLA2; LPS, lipopolyssacharide; LT, leukotriene; LO: lipoxygenase; MAPK, 
mitogen-activated protein kinase; MR, mannose receptor; NLR, NOD-like 
receptor; NOD, nucleotide oligomerization domain; PAF, platelet-activating 
factor; PAF-AH, PAF-acetylhydrolase; PAMP, pathogen-associated molecular 
pattern; PAP-1: phosphatic acid phosphatase-1; PG, prostaglandin; PIPs, 
phosphoinositides; PLA2, phospholipase A2; PRR, pathogen recognition 
receptor; RLH, RIG-I-like helicase; sPLA2, Ca2+-dependent secreted PLA2; SR, 
scavenger receptor; TLR, Toll-like receptor; UDP, uridin 5’-diphosphate. 
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 1. Introduction 
The phospholipase A2s (PLA2s) are enzymes that catalyze the hydrolysis of the 
ester bond at the sn-2 position of glycerophospholipids, generating a free fatty 
acid and a lysophospholipid. This reaction constitutes the major pathway 
through which arachidonic acid (AA) is released from glycerophospholipids 
during cellular stimulation. Free AA is the precursor of the eicosanoids, which 
include the prostaglandins, generated through cyclooxygenase-catalized 
reactions, and the leukotrienes and lipoxins, generated through lipoxygenase-
catalyzed reactions [1]. Additionally, the PLA2 reaction generates a platelet-
activating factor (PAF) precursor when the lysophospholipid product possesses 
a choline headgroup and an alkyl linkage at the sn-1 position. Thus, PLA2s are 
important signaling enzymes which regulate the generation of lipid second 
messengers of different types with key roles in regulating innate immune 
responses. In turn, direct inhibition of PLA2 would have the potential of blocking 
multiple kinds of lipid-signaling pathways at once, which could be of therapeutic 
advantage in certain settings. Targeting and inhibiting the PLA2 reaction has 
proved problematic since numerous PLA2 enzymes exist in cells with 
overlapping activation properties. Only in human, at least 22 proteins 
possessing PLA2 activity have been described [2, 3]. Thus the first step for a 
rational PLA2 drug design strategy should be to define the involvement of the 
different PLA2 classes present in cells and elucidate their roles in lipid mediator 
biosynthesis during signaling triggered by multiple innate immunity receptors. 
 
2. Phospholipase A2 
The PLA2 enzymes have systematically been classified into several group types 
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 according to their primary structure [3, 4]. The latest update to this classification, 
published in 2009 [2] included fourteen groups, most of them with several sub-
groups. Only PLA2s whose nucleotide sequence has been determined should 
be included in the classification. From a mechanistic point of view, the PLA2s 
can be grouped into two major families, namely the low-molecular mass 
enzymes (>20 kDa), which utilize a catalytic histidine, and the high molecular 
mass enzymes (<40 kDa), which utilize a catalytic serine [4,5]. For a detailed 
information on the biochemistry and function of PLA2 enzymes, the reader is 
kindly referred to recent reviews on the subject [2-8]. 
 From the point of view of cellular regulation, mammalian PLA2 enzymes 
involved in AA metabolism are frequently classified into three families, namely 
the Ca2+-dependent cytosolic PLA2s (cPLA2s), the Ca2+-dependent secreted 
PLA2 (sPLA2s), and the Ca2+-independent cytosolic PLA2s (iPLA2s) [5,7].  Of 
these families, the first two have been repeatedly implicated in AA mobilization 
in response to a variety of immunoinflammatory stimuli. Today, it is firmly 
established that the calcium-dependent cytosolic group IVA PLA2α (cPLA2α) is 
the critical enzyme in AA release (Figure 1) [9, 10] and that, depending on cell 
type and stimulation conditions, a secreted PLA2 –in particular, that belonging to 
groups IIA, V, and X– may also participate by amplifying the cPLA2α-regulated 
response [11-15]. There is no compelling evidence that iPLA2 enzymes play an 
effector role in AA mobilization in response to stimuli of the innate immune 
response [5], but these enzymes may participate in the formation of cellular AA 
pools by regulating basal AA reacylation reactions [16-18]. 
A number of agents that exert effects on cells via innate immune 
receptors elicits a series of signals that ultimately lead to increased PLA2 
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 activity. Elucidation of these signals has been the subject of much effort for the 
last twenty years. Figure 2 shows the PLA2 signal transduction mechanism 
developed over the years for major immunoinflammatory cells such as 
macrophages and mast cells. The model depicted in Fig 2 contemplates a 
scenario where the concerted action of two distinct PLA2s leads to a full AA 
release response. cPLA2α appears to be responsible for the bulk of the AA 
release, whereas the sPLA2 effects the AA release as well, but may primarily 
act to amplify the response by providing additional signals for full activation of 
the cPLA2α. The cells respond to two different kinds of signals that generate 
either immediate (min) or delayed responses (h). In the first case, the agonist 
acts on pre-existing proteins, whereas in the latter, synthesis of new protein 
effectors is a key event. In either case, the foremost event is the translocation 
and activation of cPLA2α in an intracellular compartment. The mechanism of 
activation of this enzyme has been the subject of many studies, and generally 
involves the concerted action of the mitogen-activated protein kinase (MAPK) 
cascade and transient elevations of the intracellular Ca2+ concentration [7-10]. 
Examples have been provided to indicate that cPLA2 activation may also take 
place in the absence of intracellular Ca2+ elevations [19-21]. 
Activation of cPLA2α may precede or follow the activation of a sPLA2 
which, depending on cellular type, may belong to groups IIA, V, or X. 
Depending on stimulation conditions, the cPLA2α-modulation of sPLA2 cellular 
activity may occur at a gene regulatory level (delayed responses) or at the level 
of regulation of enzyme activity itself (immediate responses). In the latter case, 
a variety of cellular mechanisms may account for this activation, from 
rearrangement of membrane phospholipids that enables further PLA2 attack, to 
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 more sophisticated biochemical mechanisms such as inactivation of 
endogenous inhibitors or Ca2+ fluxes. The situation is further complicated by the 
evidence that the sPLA2 may also act to regulate cPLA2α by various 
mechanisms, including the regulation of phosphorylation reactions. Specific 
examples are provided in the following sections. 
While it is clear that cPLA2α acts predominantly on perinuclear 
membranes, the precise site of action of the sPLA2 has been the subject of 
numerous studies. The enzyme appears to be released to the extracellular 
medium, from which it re-associates with the outer cellular surface where it 
hydrolyzes phospholipids. However recent studies have suggested that the 
enzyme is re-internalized deep into the cell, probably via the caveolae system to 
the vicinity of nuclear membranes [22, 23]. Whether the enzyme is still active in 
the cellular interior or this represents a signal termination mechanism is unclear 
at present. This is currently an area of active study. Recent data have 
suggested that sPLA2 acts intracellularly just prior secretion of the enzyme to 
the extracellular medium [24, 25]. 
 
3. Receptors of the innate immune response 
The immune system can be divided into two categories: the innate or non-
specific immunity and the adaptive or specific immunity. The latter is based on 
lymphoid cell-surface receptors generated by gene rearrangements that 
undergo somatic hypermutations in order to recognize an infinite variety of 
antigens. This response is more complex than the innate response, as the 
antigen has to be processed first. The innate or non-specific immunity is present 
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 in almost all multicellular organisms and constitutes the first line of defense 
against invading pathogens.  
The innate immune response system has the capacity to directly 
recognize a broad range of pathogens using a repertoire of receptors, the so-
called pathogen recognition receptors (PRRs) [26]. These receptors are 
encoded in the germ line of each individual and do not undergo somatic 
mutations, as is the case of the receptors of adaptive immunity. PRRs 
recognize conserved molecular patterns of foreign organisms such as viruses, 
bacteria, fungi and parasites, which are denominated pathogen-associated 
molecular patterns (PAMPs), although they are present on both pathogenic and 
non-pathogenic microorganisms. They comprise sugars, proteins and lipids, as 
well as distinct nucleic acid motifs. There are several hundred of these PAMPs, 
that directly activate immune cells, triggering a signaling cascade that lead to 
the expression of a variety of genes involved in the inflammatory and immune 
responses.  
Among the PRRs, the best characterized are the TLRs [27-32] (Figure 3). 
Up to date, thirteen TLRs have been described in mice and human, TLR10 
being expressed exclusively in human and TLR11-13 in mice [33]. In humans, 
the TLRs can be sub-divided into five subfamilies based on amino acid 
sequences, namely TLR2 (including TLR1, TLR2, TLR6 and TLR10), TLR3, 
TLR4, TLR5 and TLR9 (including TLR7, TLR8 and TLR9) [34]. In mice, TLR11, 
12 and 13 comprise another additional subfamily [35]. The TLR3 and TLR9 
families are located exclusively in endosomal compartments and are considered 
intracellular receptors [36]. 
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 Other types of PRRs include (i) CD14, co-receptor for bacterial LPS [37], 
(ii) C-type lectin receptors (CLRs) such as the mannose receptor or CD206 [38],  
dectin-1, the primary macrophage receptor for the phagocytosis of yeast [39], or 
DC-SIGN [40]; (iii) scavenger receptors (SRs), a group of receptors involved in 
receptor-mediated endocytosis of polyanionic ligands such as low density 
lipoproteins (LDL) modified by oxidation or acetylation [41]; (iv) the formyl-
methionyl-leucyl-phenylalanine (fMLP) receptor, mainly present in neutrophils 
[42]; and (v) a series of intracellular receptors such as the nucleotide 
oligomerization domain (NOD)-like receptors (NLRs) [43] or the RIG-I-like 
helicases (RLHs) [36,44]. 
On the other hand, the innate immune system also includes a series of 
receptors that do not directly recognize the pathogens, but do it so when the 
pathogens are coated with opsonins. These are the complement receptor type 3 
(CR3 or CD11b/CD18), and the Fc receptors (FcRs), and are generally 
considered the link between innate and adaptive immunities [45,46]. CR3 is the 
main receptor mediating type II phagocytosis of complement-coated particles, 
but it has been also implicated in nonopsonic phagocytosis of zymosan and 
Mycobacterium kansaii through engagement to distinct sites [47]. Thus, in a 
general sense CR3 could also be considered a PRR. 
 
4. TLRs and AA mobilization  
TLR2 - Little information is available on TLR2-mediated stimulation of PLA2 
leading to AA mobilization. Suram et al. [48] showed that, in RAW264.7 
macrophages, TLR2 acts together with dectin-1 to activating cPLA2α and 
cyclooxygenase-2 expression upon stimulation with soluble lipopeptide-2 
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 (MALP-2) and particulate β-glucan (P-βG), respectively. In bone marrow-
derived mast cells of sPLA2-V-null mice stimulated with the TLR2 agonist 
Pam3CSK4, the release of AA and the production of leukotriene C4 and 
prostaglandin D2 were diminished, as well as the phosphorylation of ERK1/2 
and cPLA2α, demonstrating a role of endogenous group V sPLA2 in TLR2-
mediated stimulation through the activation of ERK and cPLA2α [49]. Activation 
of cPLA2α via MAPK, with enhancement of AA release in mouse peritoneal 
macrophages, COX-2 induction and eicosanoid production through stimulation 
of TLR2 with the bacteria Listeria monocytogenes has also been reported [50]. 
 
TLR3 - Pindado et al. [51] studied the mechanism of activation of TLR3 
with viral dsRNA in RAW264.7 macrophages. dsRNA poly:IC induced AA 
release through cPLA2α activation, cPLA2α-independent induction of COX-2, 
increase in PGE2 production and an increase in expression of NO synthase 
(iNOS), which resulted dependent on cPLA2 and COX-2, as demonstrated by 
pharmacological approaches and knockdown gene experiments. Thus, the 
TLR3 stimulation with dsRNA leads to a signaling cascade involving activation 
of cPLA2α, induction of COX-2, with the subsequent production of PGE2 which 
in turn promotes an enhanced iNOS expression. Remarkably, no role for sPLA2 
enzymes along this cascade of activation was found. 
 
TLR4 - The stimulation of AA mobilization by TLR4 agonists has been 
extensively studied. The classic TLR4 agonist is LPS, a major component of 
Gram-negative bacterial cell walls. Although LPS on its own is a poor stimulus 
of AA release in primary cells of human and mice, it possesses a remarkable 
 11
 potency as a primer of the AA mobilization response. Thus LPS potentiates by 
several-fold the AA release response of a second stimulus that is added shortly 
after [52,53]. In macrophage-like cell lines, however, LPS is able to elicit a 
robust AA mobilization on its own, although the response takes several hours to 
fully develop. This strong activating effect of LPS on macrophage cell lines has 
been extensively used as a model system for studies aiming at understanding 
cellular regulation of PLA2 and AA mobilization for eicosanoid biosynthesis.  
Well before the TLR4 receptor was identified, Balsinde et al. [11] 
demonstrated by the use of antisense oligonucleotide approaches that approx. 
60-70% of [3H]AA released by murine macrophage-like P388D1 cells primed 
with LPS and activated with PAF was under the control of a sPLA2 enzyme. 
Further studies utilizing specific inhibitors [54] corroborated these findings and 
also provided evidence for the participation of cPLA2α in the process, thus 
providing the first direct evidences that two distinct PLA2 enzymes were 
involved in receptor-regulated AA mobilization reactions. A cross-talk between 
cPLA2α and sPLA2, where a prior activation of cPLA2 was necessary for sPLA2 
to act was established [13]. Subsequent work demonstrated that the sPLA2 
involved in these processes was a novel group V enzyme, which had been 
discovered only two years before [55]. Activation by LPS/PAF induced 
sphingomyelin synthesis, with accumulation of ceramide and diacylglycerol, 
leading to activation of group V sPLA2, probably via some sort of perturbation in 
the membrane [56].  
In other series of studies, the delayed response of P388D1 macrophage-
like cells to LPS alone was investigated [57]. LPS stimulation activates cPLA2α, 
which regulates sPLA2-V expression and in turn mobilizes AA leading to PGE2 
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 production via COX-2, an enzyme whose induction was found to depend on the 
activity of group V sPLA2 [57, 58]. These results were confirmed by Murakami et 
al.  [12], who studied the effect of various sPLA2 enzymes in AA metabolism 
when over-expressed in human embryonic kidney 293 (HEK 293) and Chinese 
hamster ovary (CHO-K1) stimulated with calcium ionophore (immediate 
response) or interleukin-1 (delayed response). In these studies it was 
demonstrated that cPLA2α, group IIA sPLA2 and group V sPLA2 all mediate AA 
release, and that a synergism exists between cPLA2α and the sPLA2 enzymes 
in AA release; cPLA2α was necessary for sPLA2 but not the opposite [12]. 
Studies by confocal microscopy of P388D1 cells stimulated with LPS 
concluded that sPLA2-V is internalized in caveolin-enriched granules through 
the perinuclear membrane, thus colocalizing with COX-2 and promoting AA 
release for subsequent production of prostaglandins [22]. Shirai et al. [59] also 
studied the localization of fusion proteins of cPLA2α and sPLA2-V in P388D1 
stimulated with PAF/LPS (primed immediate response) or LPS (delayed 
response). In the short-term stimulation, translocation of cPLA2α to 
perinuclear/Golgi membranes was observed, whereas no significant changes in 
the localization of group V sPLA2 were detected. In the long-term stimulation, 
both cPLA2α and group V sPLA2 translocated to intracellular membranes at 3 h, 
with release of AA being observed in a cPLA2α-dependent manner. 
In TLR4 knock-down experiments, Qi et al. [60] investigated the role of 
TLR4 in LPS-mediated stimulation in RAW 264.7 macrophages. In this system, 
activation of cPLA2α for eicosanoid production was found to be regulated via 
TLR4 through MyD88 and TRIF adapter proteins, with the subsequent 
activation of MAPK and the PI3K/Akt cascade, although only the first one leads 
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 to phosphorylation of cPLA2α. In human U937 macrophage-like cells and 
murine P388D1 macrophages stimulated with LPS it has been described that 
the enhanced COX-2 expression and PGE2 release is inhibited by the 
phosphatidate phosphohydrolase-1 inhibitors BEL and propranolol, and that 
diacylglycerol, product of phosphatidate phosphohydrolase-1, increases the 
inflammatory response of LPS, thus implicating phosphatidate 
phosphohydrolase-1, and more specifically its product, diacylglycerol, in the 
signaling pathway promoted by TLR4 stimulation [61]. Similar results have been 
obtained in murine macrophage RAW264.7 stimulated with the TLR4 agonist 
Kdo2-lipid A, where activation of cPLA2α is dependent on phosphatidate 
phosphohydrolase-1, which in turns activates protein kinase C through 
diacylglycerol production. However, neither phosphatidate phosphohydrolase-1 
nor protein kinase C appear to be involved in the synergistic response promoted 
by TLR4 stimulation together with ATP (sustained-Ca2+ influx) [62].  
 
TLR 7 and 8 - One study has been reported in human 
polymorphonuclear leukocytes stimulated by the synthetic agonist of TLR7 and 
8 imidazoquinoline resiquimod (R-848) [63]. Priming cells to further stimulation 
with fMLP promotes cPLA2α phosphorylation and 5-LO translocation, with the 
subsequent enhancement of AA release, biosynthesis of PAF and leukotriene 
and increase of COX-2 expression. This study shows the ability of ssRNA to 
promote synthesis of lipid mediators through the TLR8 pathway. 
 
TLR9 - TLR9 has been also implicated in AA release in macrophage-like 
cells RAW264.7 [64]. In this system, stimulation of TLR9 with CpG (a compound 
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 that is similar to bacterial DNA) leads to activation of cPLA2α and subsequent 
AA release, in a process that is dependent on p38 and Akt pathways. In 
addition, cPLA2α is crucial for enhanced expression of iNOS under TLR9 
stimulation. Furthermore, the same group demonstrated in the same system 
that activation of cPLA2α through TLR9 agonist promoted induction and JNK-
mediated release of monocyte chemoattractant protein MCP-1 [65]. Importantly, 
AA release in TLR-mediated stimulation was found to be independent on sPLA2 
enzymes, as judged by the use of the cell-permeable inhibitor scalaradial. 
 
To finish this section, two groups have comparatively studied the release 
of AA with multiple agonists for TLRs (TLR1 to 9). Buczynski et al. [66] 
characterized the eicosanoid profiles produced after activation of RAW264.7 
macrophage-like cells by a variety of TLR agonists, but no striking differences 
were appreciated among the various agonists used. Ruipérez et al. [67] utilized 
P388D1 and RAW264.7 macrophage-like cells to study the cross-talk between 
cPLA2α and group V sPLA2 in the release of AA under stimulation with agonists 
of TLR1 to 9. In this study it was found that all TLR agonists but TLR5 and 
TLR9 were able to induce AA mobilization by a mechanism involving both 
cPLA2α and sPLA2-V. The latter enzyme was reported to regulate 
phosphorylation of the former via ERK1/2. 
 
5. AA mobilization in response to non-TLR agonists  
Although much of the recent work on AA mobilization focuses mainly on 
stimulation via TLR, there is also significant data on the stimulation of AA 
mobilization via non-TLR receptors of the innate immunity. 
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 As early as 1982, the release of AA in response to IgE complexes was 
demonstrated in mouse peritoneal macrophages [68]. With the establishment of 
gene knockdown and cloning technologies, the mechanisms underlying this 
phenomenon have been characterized with detail at a molecular level. 
Fujishima et al. [14] sensitized bone marrow-derived mast cells (BMMC) from 
cPLA2α+/+ and cPLA2α-/- mice with monoclonal mouse IgE anti-trinitrophenyl 
(TNP) ascites and then stimulated them with TNP-BSA in order to mimic a 
FcεRI-dependent activation. Under these experimental conditions they failed to 
observe detectable production of PGD2 and LTC4 in cPLA2α-/- mice, but robust 
generation of the two eicosanoids was found in cPLA2α+/+ mice, demonstrating 
the essential role of cPLA2α for the immediate production of eicosanoids via 
engagement of FcεRI. Work by the same group [69] also demonstrated that 
group V sPLA2 amplifies the response of cPLA2α, inducing a FcεRI-dependent 
COX-2 production and delaying the production of PGD2, but not of LTC4, in 
mouse BMMC.  
The classical model for AA mobilization studies in the human neutrophil 
is via activation of the fMLP receptor, which interacts with f-Met-Leu-Phe, a 
bacterial chemotactin tripeptide. Stimulation of neutrophils with fMLP induces 
phosphorylation of cPLA2α and AA release [70]. Interestingly, the 
phosphorylation of the enzyme was MAPK-independent, but AA release was 
inhibited by inhibitors of p38 MAPK and ERK, suggesting that these proteins 
play a role downstream cPLA2α activation, perhaps by affecting the 
translocation of the enzyme where its substrate is located, or by reducing the 
increase in the intracellular levels of Ca2+ [70]. Two recent studies from the 
Rubin laboratory described in detail the importance of sPLA2 in the human 
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 neutrophil response to agonists of the fMLP receptor. In the first paper [71] a 
central role in governing the AA release was attributed to cPLA2α and an 
accessory secondary role was found for an unidentified sPLA2 enzyme, and the 
suggestion was made that such sPLA2 activity was somehow regulated by 
cPLA2α. In a second study [72] the authors observed that production of 
leukotriene B4 by fMLP-stimulated neutrophils was insensitive to sPLA2 
inhibitors, suggesting that production of this particular eicosanoid depends only 
on cPLA2α activation. 
 
6. The AA mobilization response to zymosan 
For years, zymosan has constituted the classical stimulus for studies of 
AA mobilization in immunoinflammatory cells. Consequently, a wealth of data 
has accumulated on the role of PLA2-mediated lipid pathways in response to 
this agonist. Zymosan is a preparation of yeast cell walls consisting of protein-
carbohydrate complexes, mainly formed by β-glucan and mannan. Zymosan 
has the ability to bind to different receptors in the macrophage surface 
depending on whether the particles are opsonized or not. Opsonized zymosan 
binds mainly to FcR and CR3, and although CR3 has also the capacity of 
binding nonopsonized zymosan by different sites, it has been reported not to 
induce AA release in murine peritoneal macrophages [73]. On the other hand, 
unopsonized zymosan binds preferentially to dectin-1 and, to a lesser extent, 
TLR2/TLR6.  
Some three decades ago the release of AA and the production of 
prostanglandins and leukotrines in murine peritoneal macrophages stimulated 
with unopsonized zymosan was demonstrated [74-76]. Dissection of the lipid 
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 pathways involved indicated a preeminent, if not exclusive, role for a PLA2-like 
activity in effecting the AA release [77-79]. Such a PLA2 activity was identified to 
correspond to that of cPLA2α, and its cellular regulation by Ca2+ transients and 
phosphorylation was established [80, 81].   
At that time the different PLA2s present in cells and the receptors 
responsible for the recognition of zymosan were poorly characterized. With the 
cloning, characterization and better understanding of the function of the different 
PLA2 groups, it was possible to study of stimulation mediated by zymosan in a 
much more detailed way. By using mice lacking cPLA2α by genetic ablation, 
Gijón et al. [21] unambiguously demonstrated that this enzyme is essential for 
the AA release and eicosanoid production in response to unopsonized 
zymosan. Phosphorylation of cPLA2α on Ser 505 in response to zymosan was 
found to be mediated by ERK and p38 MAPK, although the molecular 
significance of such a phosphorylatiom reaction still remains poorly understood 
[82]. Subsequently it was shown that in addition to translocating to perinuclear 
membranes, cPLA2α also translocates to the phagosome during the 
phagocytosis of particles of unopsonized zymosan in mouse peritoneal 
macrophages [83]. Utilizing opsonized zymosan particles, Casas et al. [84] 
demonstrated in human monocyte-derived macrophages that translocation was 
regulated by the activation of JNK, which is responsible for the phosphorylation 
of cPLA2α on Ser 505. In this study no translocation of other PLA2 enzymes 
present in the cells to the phagosome could be observed [84]. 
With regard to the involvement of sPLA2 family members in the 
amplification of cPLA2α signaling, Satake et al. [85] generated mice lacking 
group V sPLA2 and observed that peritoneal murine macrophages from these 
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 mice produced lower quantities of leukotriene C4 and prostaglandin E2 in 
response to zymosan compared to cells from wild-type mice. Following this 
observation, the same group [86] showed in peritoneal murine macrophages 
that group V sPLA2 translocates to the phagosome during the phagocytosis of 
unopsonized zymosan particles. Staining of LTC4 during phagocytosis 
demonstrated that this leukotriene was synthesized at the phagosome itself. 
Furthermore, peritoneal macrophages from group V sPLA2-null mice presented 
a lower phagocytosis of zymosan particles. The suggestion was made that 
recruitment of sPLA2 to the phagosome is induced in order to amplify the signal 
of the cPLA2α already present in the phagosome, where both enzymes co-
localize.  
Suram et al. [48] observed that the AA release induced incubating mouse 
peritoneal macrophages with unopsonized zymosan is blocked by a highly 
purified preparation of soluble β-(1,3)-glucan phosphate. It was demonstrated in 
RAW 264.7 macrophages overexpressing dectin-1 or SIGNR1, a homologous 
receptor to DC-SIGN, that the receptor implicated in the activation of cPLA2α 
and release of AA is dectin-1. In addition, zymosan induced the expression of 
COX-2 and the increase in the production of PGD2 only in cells overexpressing 
dectin-1. Similarly, in human monocyte-derived dendritic cells it has been 
shown that unopsonized zymosan binds dectin-1 and DC-SIGN, and induces 
phosphorylation of Syk, activation of cPLA2α and the subsequent mobilization of 
AA and COX-2 expression [87]. 
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 Figure Legends 
 
Figure 1. Ribbon diagram of cPLA2α. The C2 domain on the left mediates 
interaction of the enzyme with membranes via binding of two Ca2+ atoms. The 
active site Ser 228 on the catalytic domain is highlighted, as is the 
phosphorylation site Ser 505. 
 
Figure 2. Cross-talk between PLA2 enzymes during activation of cells via innate 
immune receptors. For details see text. 
 
Figure 3. The Toll-like receptor family and its ligands. 
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